A MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF SOLIFENACIN SUCCINATE SUSPENSION IN PEDIATRIC SUBJECTS FROM 5 TO LESS THAN 18 YEARS OF AGE WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO).

被引：0
|
作者：
Bosman, B. [1 ]
Tannenbaum, S. [1 ]
Winklewski, P. [1 ]
Den Adel, M. [1 ]
Newgreen, D. [1 ]
Baka-Ostrowska, M. [1 ]
机构：
[1] Pomnik Ctr Zdrowia Dziecka Warsaw, Warsaw, Poland
来源：
NEUROUROLOGY AND URODYNAMICS | 2013年 / 32卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
296
引用
收藏
页码：932 / 933
页数：2
相关论文
共 25 条
  • [21] Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor
    Garralda, Elena
    Boni, Valentina
    Baz, David Vincente
    Chaudhry, Arvind
    Bazo, Ignacio Gil
    Gutierrez, Martin
    Malhotra, Jyoti
    Alonso, Casal Guzman
    Gambardella, Valentina
    Chisamore, Michael
    Zhou, Renke
    Tea, Maria
    Doroshow, Deborah
    CANCER RESEARCH, 2024, 84 (07)
  • [22] A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799544 (ARRY-134) as a single agent and in combination with PF-07799933 BRAF dimer inhibitor, in participants 16 years and older with advanced solid tumors.
    Beck, J. Thaddeus
    Shepard, Dale Randall
    Dumas, Olivier
    Pezo, Rossanna C.
    Rose, April A. N.
    Ong, Michael
    Saleh, Ramy R.
    Iwamoto, Fabio
    Gray, Juliette
    Wollenberg, Lance
    Maity, Arnab
    Sturtz, Keren
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 (Lacutoclax) As Monotherapy and in Combination with Azacitidine in Subjects with Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
    Burgues, Juan Miguel Bergua
    Koenig, Kristin
    Montesinos, Pau
    Bixby, Dale L.
    Burke, Patrick W.
    Daver, Naval
    Anthony, Stephen P.
    Tan, Fenlai
    Chen, Yi
    Chen, Yu
    Aviles, Ignacio Casas
    Curran, Emily K.
    BLOOD, 2024, 144 : 6009 - 6010
  • [24] Interim Safety, Biomarker, and Efficacy Data From Imagine-1: A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Single Dose, ICM Administration of PBGM01 in Subjects with Type I (Early Onset) and 10. Type IIa (Late Onset) Infantile GM1 Gangliosidosis (GM1)
    Weinstein, David A.
    Hastings, Caroline A.
    Day-Salvatore, Debra-Lynn
    Ficicioglu, Can
    Whitley, Chester B.
    Inbar-Feigenberg, Michal
    Bernard, Genevieve
    Giugliani, Roberto
    Baruteau, Julien
    Ezgu, Fatih S.
    Jarnes, Jeanine R.
    Ni, Yan G.
    Nagilla, Pruthvi
    Ballard, Victoria L.
    Haws, Thomas F.
    Gelb, Michael H.
    Forman, Mark S.
    MOLECULAR THERAPY, 2022, 30 (05) : 5 - 6
  • [25] Updated interim safety, biomarker, and efficacy data from Imagine-1: A phase 1/2 open-label, multicenter study to assess the safety, tolerability, and efficacy of a single dose, intra-cisterna magna (ICM) administration of PBGM01 in subjects with type I (early onset) and type IIA (late onset) infantile GM1 gangliosidosis (GM1)
    Jarnes, Jeanine R.
    Hastings, Caroline A.
    Ficicioglu, Can H.
    Day-Salvatore, Debra-Lynn
    Giugliani, Roberto
    Baruteau, Julien
    Whitley, Chester B.
    Inbar-Feigenberg, Michal
    Bernard, Genevieve
    Ezgu, Fatih S.
    Ni, Yan G.
    Miller, Michelle
    Gelb, Michael H.
    Nagilla, Pruthvi
    Johnstone, Rose
    Elsasser, Patricia
    Cunningham, Elizabeth
    Ballard, Victoria
    Haws, Thomas F.
    Forman, Mark S.
    Weinstein, David A.
    MOLECULAR GENETICS AND METABOLISM, 2023, 138 (02) : 68 - 68
123